Tech Center 1600 • Art Units: 1622 1624
This examiner grants 79% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18009311 | 2,3-DISUBSTITUTED PYRIDO[3,4-B]PYRAZINE-CONTAINING COMPOUNDS AS KINASE INHIBITORS | Final Rejection | Purdue Research Foundation |
| 18124389 | TETRAHYDROBENZOFURODIAZEPINONE COMPOUND AND PHARMACEUTICAL USE THEREOF | Final Rejection | Japan Tobacco Inc. |
| 17494759 | FUNCTIONALIZED PYRANO[2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE | Non-Final OA | The Texas A&M University System |
| 18017108 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | Final Rejection | The Regents of the University of Michigan |
| 18002122 | N-1 BRANCHED IMIDAZOQUINOLINES, CONJUGATES THEREOF, AND METHODS | Non-Final OA | Solventum Intellectual Properties Company |
| 18571013 | A SMALL MOLECULE TNF-a INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Non-Final OA | FUDAN UNIVERSITY |
| 18671711 | PLINABULIN COMPOSITIONS | Non-Final OA | BeyondSpring Pharmaceuticals, Inc. |
| 18042352 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | Non-Final OA | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
| 18008282 | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 18272493 | METHOD FOR CONTROLLING WEEDS | Non-Final OA | KUMIAI CHEMICAL INDUSTRY CO., LTD. |
| 18257373 | CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHOD OF PREPARATION THEREOF | Non-Final OA | Jazz Pharmaceuticals Research UK Limited |
| 18317352 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Final Rejection | Prelude Therapeutics Incorporated |
| 18551281 | SMALL MOLECULES FOR THE TREATMENT OF KINASE-RELATED DISEASES | Non-Final OA | Athos Therapeutics, Inc. |
| 18016295 | COMPOUNDS FOR TREATING HEPATOCELLULAR CARCINOMA | Non-Final OA | UNIVERSIDAD DE CÓRDOBA |
| 18276295 | PHARMACEUTICAL DOSAGE FORM | Non-Final OA | Mark HASLETON |
| 18269837 | NRF2-ACTIVATING COMPOUND | Final Rejection | SENJU PHARMACEUTICAL CO., LTD. |
| 18252962 | NEW THERAPY CONCEPT FOR THE TREATMENT OF CORONA INFECTIONS, ESPECIALLY COVID-19 INFECTIONS | Non-Final OA | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbh |
| 18007960 | Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof | Non-Final OA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH |
| 18245676 | PROGRAMMED CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Final Rejection | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences |
| 18021508 | LMO2 PROTEIN INHIBITORS | Non-Final OA | UNIVERSITY OF OXFORD |
| 18015465 | POLYCYCLIC CAP-DEPENDENT ENDONUCLEASE INHIBITORS FOR TREATING OR PREVENTING INFLUENZA | Non-Final OA | COCRYSTAL PHARMA, INC. |
| 18015041 | WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY | Non-Final OA | KLOTHO THERAPEUTICS, INC. |
| 18007797 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Non-Final OA | Kineta, Inc. |
| 17998436 | QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS | Final Rejection | ASSOCIATION INSTITUT DE MYOLOGIE |
| 17942508 | PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS | Non-Final OA | Fundacion del sector publico estatal centro nacional de investigaciones oncologicas Carlos III (F.S. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy